Alivus Life Sciences Q2 Results
- BSE: 543322
- NSE: ALIVUS
- ISIN: INE03Q201024
- Sector: Biotechnology & Drugs
BSE
1,309.15
-34.00 (-2.53%)
-34.00 (-2.53%)Volume2.36 K
Updated: Fri 16 Oct, 2026 | 15:55:17
NSE
1,309-32.80 (-2.44%)
-32.80 (-2.44%)Volume35.95 K
Updated: Fri 16 Oct, 2026 | 15:29:50
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
Quarter ended Sep 25
Note: Comparison is on QoQ basis
Quarterly - Alivus Life Sciences Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 26 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 427.25 | 449.29 | -4.33% | 387.61 | 10.22% |
| Depreciation/ Amortization | 18.44 | 20.59 | 8.03% | 15.09 | 22.14% |
| Operating Income | 160.73 | 191.13 | 3.54% | 119.27 | 34.77% |
| Net Income | 130.03 | 160.08 | 6.99% | 95.32 | 36.42% |
| Other Operating Expenses Total | 93.49 | 105.41 | -4.18% | 84.89 | 10.14% |
| Net Income Before Taxes | 174.14 | 212.22 | 6.84% | 127.46 | 36.63% |
| Total Revenue | 587.98 | 640.41 | -2.30% | 506.88 | 16.00% |
| Selling/ General/ Admin Expenses Total | 66.40 | 68.25 | 7.83% | 62.44 | 6.34% |
| Diluted Normalized EPS | 10.58 | 13.01 | 7.09% | 7.75 | 36.52% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.